Clementina López-Medina1, Yolanda Jiménez-Gómez2, Anna Moltó3, Ruxandra Elena Schiotis4, Helena Marzo-Ortega5, Floris A van Gaalen6, Salih Ozgocmen7, Maxime Dougados3, Jerusalem Calvo-Gutiérrez2, M Carmen Castro-Villegas2, Eduardo Collantes-Estévez2, Pilar Font-Ugalde2. 1. Maimónides Institute for Research in Biomedicine of Cordoba (IMIBIC), 14004 Córdoba, Spain; Rheumatology Department, Reina Sofia University Hospital, Avda. Menendez Pidal, s/n., 14004 Córdoba, Spain; Córdoba University (UCO), 14004 Córdoba, Spain. Electronic address: clementinalopezmedina@gmail.com. 2. Maimónides Institute for Research in Biomedicine of Cordoba (IMIBIC), 14004 Córdoba, Spain; Rheumatology Department, Reina Sofia University Hospital, Avda. Menendez Pidal, s/n., 14004 Córdoba, Spain; Córdoba University (UCO), 14004 Córdoba, Spain. 3. Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP, 75014 Paris, France; Inserm (U1153), Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, 75014 Paris, France. 4. Iuliu Hatieganu, University of Medicine and Pharmacy and Department of Rheumatology, SCBI, 400012 Cluj-Napoca, Romania. 5. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Alberton Hospital, LS7 4SA Leeds, UK. 6. Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. 7. Department of Rheumatology, Medicalpark Gaziosmanpasa, 34250 Istambul, Turkey.
Abstract
OBJECTIVES: The objectives of this study were: (1) to compare the prevalence of cardiovascular disease and cardiovascular risk factors among different phenotypes of spondyloarthritis (SpA); (2) to assess the differences in cardiovascular disease and cardiovascular risk factors between two geographical areas, i.e. Northern Europe vs. Mediterranean region; (3) to identify potential predictive factors for high Framingham Risk Score regarding disease features in SpA and geographical area. METHODS: Ancillary analysis of the international, multicentric, observational, cross-sectional ASAS-COMOSPA study. Cardiovascular disease and cardiovascular risk factors were compared depending on SpA phenotype and geographical regions. Potential factors associated with higher cardiovascular risk (i.e. Framingham Risk Score) were determined by a multiple logistic regression. RESULTS: The most frequent cardiovascular risk factor and cardiovascular disease were smoking (31.2%) and ischemic heart disease (3.2%), respectively. Regarding SpA phenotype, axial SpA patients showed significantly lower prevalence (P<0.05) of hypertension (19.2% vs. 33.8% vs. 26.6% for axial, peripheral and mixed phenotypes, respectively), type 2 diabetes mellitus (4.3% vs. 8.5% vs. 7.4%), dyslipidemia (13.9% vs. 28.4% vs. 15.2%) and ischemic heart disease (2.4% vs. 7.0% vs. 3.2%). Regarding geographical area, a higher frequency of hypertension (34.7% vs. 19.4%,), dyslipidemia (19.3% vs. 14.4%), obesity (29.3% vs. 20.7%) and ischemic heart disease (6.2% vs. 1.8%) was observed for Northern Europe vs. Mediterranean Region, respectively. CONCLUSIONS: Our results suggest that SpA phenotype and geographical area are associated with the prevalence of cardiovascular risk factors and the cardiovascular risk itself, observed in patients in the ASAS-COMOSPA cohort.
OBJECTIVES: The objectives of this study were: (1) to compare the prevalence of cardiovascular disease and cardiovascular risk factors among different phenotypes of spondyloarthritis (SpA); (2) to assess the differences in cardiovascular disease and cardiovascular risk factors between two geographical areas, i.e. Northern Europe vs. Mediterranean region; (3) to identify potential predictive factors for high Framingham Risk Score regarding disease features in SpA and geographical area. METHODS: Ancillary analysis of the international, multicentric, observational, cross-sectional ASAS-COMOSPA study. Cardiovascular disease and cardiovascular risk factors were compared depending on SpA phenotype and geographical regions. Potential factors associated with higher cardiovascular risk (i.e. Framingham Risk Score) were determined by a multiple logistic regression. RESULTS: The most frequent cardiovascular risk factor and cardiovascular disease were smoking (31.2%) and ischemic heart disease (3.2%), respectively. Regarding SpA phenotype, axial SpA patients showed significantly lower prevalence (P<0.05) of hypertension (19.2% vs. 33.8% vs. 26.6% for axial, peripheral and mixed phenotypes, respectively), type 2 diabetes mellitus (4.3% vs. 8.5% vs. 7.4%), dyslipidemia (13.9% vs. 28.4% vs. 15.2%) and ischemic heart disease (2.4% vs. 7.0% vs. 3.2%). Regarding geographical area, a higher frequency of hypertension (34.7% vs. 19.4%,), dyslipidemia (19.3% vs. 14.4%), obesity (29.3% vs. 20.7%) and ischemic heart disease (6.2% vs. 1.8%) was observed for Northern Europe vs. Mediterranean Region, respectively. CONCLUSIONS: Our results suggest that SpA phenotype and geographical area are associated with the prevalence of cardiovascular risk factors and the cardiovascular risk itself, observed in patients in the ASAS-COMOSPA cohort.
Authors: María Lourdes Ladehesa-Pineda; Iván Arias de la Rosa; Clementina López Medina; María Del Carmen Castro-Villegas; María Del Carmen Ábalos-Aguilera; Rafaela Ortega-Castro; Ignacio Gómez-García; Pedro Seguí-Azpilcueta; Yolanda Jiménez-Gómez; Alejandro Escudero-Contreras; Chary López Pedrera; Nuria Barbarroja; Eduardo Collantes-Estévez Journal: Ther Adv Musculoskelet Dis Date: 2020-12-30 Impact factor: 5.346
Authors: Iván Ferraz-Amaro; Javier Rueda-Gotor; Fernanda Genre; Alfonso Corrales; Ricardo Blanco; Virginia Portilla; Iñigo González Mazón; Javier Llorca; Rosa Expósito; Esther F Vicente; Juan Carlos Quevedo-Abeledo; Carlos Rodríguez-Lozano; Rafaela Ortega-Castro; María Lourdes Ladehesa-Pineda; Cristina Fernández-Carballido; M Paz Martínez-Vidal; David Castro-Corredor; Joaquín Anino-Fernández; María Luz García Vivar; Eva Galíndez-Agirregoikoa; Diana Peiteado; Chamaida Plasencia-Rodríguez; Esther Montes Perez; Carlos Fernández Díaz; Santos Castañeda; Miguel Ángel González-Gay Journal: Ther Adv Musculoskelet Dis Date: 2021-07-28 Impact factor: 5.346